![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Betalutin (177Lu lilotomab satetraxetan), is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) for the treatment of Hodgkin B-cell lymphoma.
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2022
Details:
Betalutin® (177Lu Lilotomab Satetraxetan), showed signs of efficacy in this frail, elderly and difficult-to-treat patient population, the independent expert panel reported that the efficacy data are less promising than the data reported from the Phase 2a LYMRIT 37-01 trial.
Lead Product(s): 177Lu Lilotomab Satetraxetan,Lilotomab
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 21, 2022
Details:
The primary objective of the PARADIGME trials is to determine the effectiveness of Betalutin (177Lu Lilotomab Satetraxetan), a novel single-dose radioimmunotherapy that targets CD37, an antigen found on the surface of tumour cells of Follicular Lymphoma.
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
106 patients has been enrolled for PARADIGME, ongoing pivotal Phase 2b trial of Betalutin (177Lu lilotomab satetraxetan) for the treatment of anti-CD20 refractory follicular lymphoma.PARADIGME data to be reported in second half of 2022.
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 07, 2022
Details:
Betalutin® (177Lu-lilotomab satetraxetan), an anti-CD37 beta-emitting radioimmuno conjugate has shown an encouraging efficacy and safety profile in 3rd line NHL patients who are refractory to anti-CD20-based treatments.
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2021
Details:
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting radioimmunotherapy designed to advance the treatment of non-Hodgkin's lymphoma (NHL).
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: ICON Clinical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021
Details:
Nordic Nanovector has completed enrolment into the LYMRIT 37-05 Phase 1 clinical trial of Betalutin® (177Lu lilotomab satetraxetan) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) not eligible for autologous stem cell transplantation (ASCT).
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2020
Details:
Data from this cohort is expected in H1'2021 and will be analysed alongside the data generated from the first cohort of patients receiving 10 MBq/kg Betalutin®/40mg lilotomab.
Lead Product(s): 177Lu Lilotomab Satetraxetan,Rituximab
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 19, 2020
Details:
The study found that Betalutin (an anti-CD37 radioimmunoconjugate) acted synergistically with rituximab (anti-CD20 immunotherapy) to suppress tumour growth in a rituximab-resistant xenograft NHL mouse model.
Lead Product(s): 177Lu Lilotomab Satetraxetan,Rituximab
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 08, 2020
Details:
The data presented in this paper are aligned with the preliminary results presented by Dr Kolstad at the American Society of Hematology medical conference in December 2018:Overall response rate (ORR) was 61% and complete response (CR) was 30% for all 74 patients.
Lead Product(s): 177Lu Lilotomab Satetraxetan
Therapeutic Area: Oncology Product Name: Betalutin
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 03, 2020